par Meunier, Françoise 
;Paesmans, Marianne ;Autier, Philippe
Référence European Journal of Cancer Part B: Oral Oncology, 30, 3, page (196-199)
Publication Publié, 1994
;Paesmans, Marianne ;Autier, PhilippeRéférence European Journal of Cancer Part B: Oral Oncology, 30, 3, page (196-199)
Publication Publié, 1994
Article révisé par les pairs
| Résumé : | This report focuses on the value of antifungal prophylaxis with antifungal drugs in preventing oropharyngeal candidiasis. Randomised trials comparing non-AIDS immunocompromised patients receiving or not an oral antifungal agent were reviewed. Colonisation of the throat with Candida albicans is a risk factor, principally when cultures for this species of yeasts remain positive after initiation of the prophylaxis. The results of the trials were meta-analysed and we obtained a combined odds ratio for developing oropharyngeal candidiasis of 0.15 when under antifungal prophylaxis (confidence interval at 95%: 0.10-6.22, χ2 statistic of 90.77, P < 0.0001). We conclude that there is a strong beneficial effect of antifungal prophylaxis against the occurrence of oropharyngeal candidiasis. However, up to now, no study has correctly assessed the value of nystatin as a prophylactic agent against oropharyngeal candidiasis. |
